Revvity Inc (RVTY)

Currency in USD
115.02
+3.63(+3.26%)
Closed·
115.020.00(0.00%)
·
RVTY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
110.81115.84
52 wk Range
81.22118.30
Key Statistics
Prev. Close
111.39
Open
112.45
Day's Range
110.81-115.84
52 wk Range
81.22-118.3
Volume
2.15M
Average Volume (3m)
1.56M
1-Year Change
33.8999%
Book Value / Share
64.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RVTY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
119.40
Upside
+3.81%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Revvity Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
11 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 119.40
(+3.81% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Bernstein SocGen Group
Hold120.00+4.33%115.00MaintainAug 05, 2026
Stifel
Hold110.00-4.36%100.00MaintainAug 05, 2026
Baird
Buy128.00+11.28%117.00MaintainJul 13, 2026
Bernstein SocGen Group
Hold115.00-0.02%-New CoverageJun 25, 2026
Wolfe Research
Hold---New CoverageJun 01, 2026

Revvity Inc Earnings Call Summary for Q2/2026

  • Revvity Q2 adjusted EPS of $1.41 beat estimates by 16.5%; revenue of $729.68M topped forecasts by 3.7%, though shares fell 3.68% premarket.
  • Adjusted operating margin reached 29.3% vs. 27% outlook; free cash flow hit $184M with 117% conversion of adjusted net income.
  • Company raised full-year guidance: organic growth to 4-5% from 3-4%; adjusted EPS to $5.30-$5.40 from $5.20-$5.30; margin up 30bps to 28.7%.
  • Management cited increasing AI-related orders and improving customer demand, though half of EPS beat came from one-time tariff refunds and tax benefits.
  • Diagnostics segment drove growth with 11% organic gain; life sciences fell 3% organically on software weakness and timing effects in instruments.
Last Updated: 04/08/2026, 13:44
Read Full Transcript

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
1.41 / 1.21
Revenue / Forecast
729.68M / 703.39M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.09%
Dividend Yield
0.25%
Industry Median 1.51%
Annualised payout
0.28
Paid quarterly
5-Years Growth
-12.94%
Growth Streak

RVTY Income Statement

Compare RVTY to Peers and Sector

Metrics to compare
RVTY
Peers
Sector
Relationship
P/E Ratio
54.1x25.4x−0.4x
PEG Ratio
−4.690.840.00
Price/Book
1.8x2.6x2.6x
Price / LTM Sales
4.4x2.1x3.0x
Upside (Analyst Target)
6.2%0.0%51.8%
Fair Value Upside
Unlock14.2%7.2%Unlock

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
79.44M71.21%9.15B
Other Institutional Investors
38.52M28.79%4.44B
Public Companies & Retail Investors
0.000.00%0.00
Total
117.97M100.00%13.59B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.28.95%32,296,0853,721,155
T. Rowe Price Capital Appreciation Fund, Inc.10.07%11,237,0611,294,734

People Also Watch

400.00
WAT
+0.99%
117.22
NOW
-0.78%
519.17
WDC
-5.36%
49.99
FAST
+0.56%
159.92
TJX
+1.50%

FAQ

What Is the Revvity (RVTY) Stock Price Today?

The Revvity stock price today is 115.02 USD.

What Stock Exchange Does Revvity Trade On?

Revvity is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Revvity?

The stock symbol for Revvity is "RVTY."

What Is the Revvity Market Cap?

As of today, Revvity market cap is 12.83B USD.

What Is Revvity's Earnings Per Share (TTM)?

The Revvity EPS (TTM) is 2.09.

When Is the Next Revvity Earnings Date?

Revvity will release its next earnings report on Nov 02, 2026.

From a Technical Analysis Perspective, Is RVTY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Revvity Stock Split?

Revvity has split 4 times.

How Many Employees Does Revvity Have?

Revvity has 11000 employees.

What is the current trading status of Revvity (RVTY)?

As of Aug 06, 2026, Revvity (RVTY) is trading at a price of 115.02 USD, with a previous close of 111.39 USD. The stock has fluctuated within a day range of 110.81 USD to 115.84 USD, while its 52-week range spans from 81.22 USD to 118.30 USD.

What Is Revvity (RVTY) Price Target According to Analysts?

The average 12-month price target for Revvity is 119.40 USD, with a high estimate of 145 USD and a low estimate of 90 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +3.81% Upside potential.

What Is the RVTY Premarket Price?

RVTY's last pre-market stock price is 112.52 USD. The pre-market share volume is 580.00, and the stock has decreased by 1.13, or 1.01%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.